Jean-Jacques Kiladjian/LinkedIn
Oct 17, 2026, 17:20
Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
Jean-Jacques Kiladjian, Head of Clinical Research Department of Inserm, Professor of Medicine at the University of Paris Cité, President of the FIM, shared a post on LinkedIn:
”Happy and grateful for the invitation to join the MPN Horizons 2026 conference, where advocates and doctors come together!
A beautiful room fully booked with patients and doctors from all around the world (including 🇦🇲 !) discussing together how to improve the care of patients with myeloproliferative neoplasms MPN, starting from patients’ needs.
My task today: what is in the pipeline for polycythemia vera?”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period
-
Oct 17, 2026, 16:24W. Alberto Sifuentes Giraldo: Exploring Peripheral Macrovascular Thrombosis in CAPS
-
Oct 17, 2026, 16:17Rishabh Jain: Could Rusfertide Transform Polycythemia Vera Management?